126 related articles for article (PubMed ID: 32060361)
41. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
Abdelfatah S; Fleischer E; Klinger A; Wong VKW; Efferth T
Invest New Drugs; 2020 Feb; 38(1):1-9. PubMed ID: 30877426
[TBL] [Abstract][Full Text] [Related]
42. A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.
Akdeli N; Riemann K; Westphal J; Hess J; Siffert W; Bachmann HS
Mol Cancer; 2014 Apr; 13():87. PubMed ID: 24767679
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
44. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
45. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
46. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
47. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
48. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
[TBL] [Abstract][Full Text] [Related]
49. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
50. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
51. PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.
Pezuk JA; Valera ET; Brassesco MS
Curr Drug Targets; 2016; 17(14):1661-1672. PubMed ID: 26302797
[TBL] [Abstract][Full Text] [Related]
52. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
54. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
55. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
56. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Liu N; Hu G; Wang H; Li Z; Guo Z
J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
[TBL] [Abstract][Full Text] [Related]
57. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.
Deng H; Jiang Q; Yang Y; Zhang S; Ma Y; Xie G; Chen X; Qian Z; Wen Y; Li J; Yang J; Chen L; Zhao X; Wei Y
Cancer Biol Ther; 2011 Feb; 11(4):401-9. PubMed ID: 21150280
[TBL] [Abstract][Full Text] [Related]
58. Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1.
Aspinall CF; Zheleva D; Tighe A; Taylor SS
Oncotarget; 2015 Nov; 6(34):36472-88. PubMed ID: 26472023
[TBL] [Abstract][Full Text] [Related]
59. Biological impact of freezing Plk1 in its inactive conformation in cancer cells.
Keppner S; Proschak E; Kaufmann M; Strebhardt K; Schneider G; Spänkuch B
Cell Cycle; 2010 Feb; 9(4):761-73. PubMed ID: 20139717
[TBL] [Abstract][Full Text] [Related]
60. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
